iOnctura

Precision drugs that simultaneously target multiple tumor survival pathways

iOnctura is a clinical stage biopharmaceutical company focusing on novel therapeutics to treat tumors burdened by stroma and immune mediated resistance. Company’s pipeline consists of two clinical stage small molecule programs against PI3kd and ATX and multiple preclinical programs.  iOnctura is supported by a world renowned scientific advisory board and, with its access to CRT’s drug discovery labs and network of academic collaborators, is well-positioned to rapidly establish novel combination therapies in the field of cancer immunology. Headquartered in Geneva, Switzerland, iOnctura was founded by M Ventures in June 2017.